Previous close | 1.4000 |
Open | 1.4000 |
Bid | 0.0500 |
Ask | 1.6500 |
Strike | 150.00 |
Expiry date | 2023-11-17 |
Day's range | 1.4000 - 1.4000 |
Contract range | N/A |
Volume | |
Open interest | 10 |
Charles River's (CRL) new RightSource facility is likely to provide services to the Stevenage advanced therapy biocluster.
WILMINGTON, Mass., September 26, 2023--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its lentiviral vector (LVV) manufacturing platform, Lentivation™. The platform has the capability to reduce LVV manufacturing timelines for gene and gene-modified cell therapies by up to 60 percent, translating to fewer than seven months compared to traditional manufacturing workflows.
STEVENAGE, United Kingdom, September 25, 2023--Charles River opens purpose-built lab offering GMP QC test capabilities to Stevenage biocluster.